Metocard

Metoprolol tartrate, the active ingredient in Metocard, is a selective β1‑adrenergic receptor blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension, angina pectoris, chronic heart failure, and post‑myocardial infarction in adult patients.

GNH USA supplies Metocard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under GMP conditions.

Metocard (metoprolol tartrate) is a beta‑blocker used to manage cardiovascular conditions that involve elevated blood pressure or cardiac workload.

Hypertension: lowers systolic and diastolic blood pressure. Angina pectoris: reduces myocardial oxygen demand and relieves chest pain. Heart failure: improves left‑ventricular function and reduces hospitalisation risk. Post‑myocardial infarction: decreases the likelihood of recurrent infarction and mortality.

Metocard may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Cold extremities - Gastrointestinal upset (nausea, abdominal discomfort) - Sleep disturbances or vivid dreams

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma or COPD - Acute decompensated heart failure - Depression or mood changes - Allergic reactions such as rash, angio‑edema, or anaphylaxis

When prescribing Metocard, clinicians should consider several safety measures.

Dose adjustment in renal impairment: reduce dose as needed. Monitor heart rate and blood pressure: check regularly during therapy. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Caution in asthma or COPD: may provoke bronchospasm. Pregnancy and lactation: use only if benefits outweigh risks. Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Metocard can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Concomitant use with non‑selective beta‑blockers: additive bradycardia. - Combination with calcium‑channel blockers (verapamil, diltiazem): risk of severe AV block. - Co‑administration with potent CYP2D6 inhibitors (e.g., quinidine, paroxetine): may increase plasma levels. - Concurrent clonidine withdrawal: precipitates hypertensive crisis.

Moderate Interactions (Monitor Closely): - Co‑administration with diuretics: may enhance hypotensive effect. - Use with insulin or oral hypoglycemics: may mask hypoglycaemia symptoms. - Concurrent NSAIDs: may reduce antihypertensive efficacy.